SAN DIEGO, Jan. 06, 2026 — Leads & Copy — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference.
The conference is being held at the Westin St. Francis in San Francisco, California.
Management is scheduled to present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time. They will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
Erasca’s mission is to erase cancer. The company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca was co-founded by pioneers in precision oncology and RAS targeting to create therapies and combination regimens designed to shut down the RAS/MAPK pathway for cancer treatment.
The company believes its team’s capabilities and experience, guided by its scientific advisory board of experts in the RAS/MAPK pathway, uniquely position it to achieve its mission.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca
